Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.70 -1.39 (-2.78%)

Streaming Delayed Price Updated: 10:21 AM EDT, Mar 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

35 36 Next >

Is This News a Setback or a Step Forward for CRISPR Therapeutics? ↗

December 06, 2023

It's important to look at the news through a long-term lens.

Via The Motley Fool

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

December 06, 2023

Via Benzinga

The Latest Analyst Ratings for CRISPR Therapeutics ↗

December 05, 2023

Via Benzinga

CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases ↗

December 05, 2023

Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T

Via Benzinga

Better Growth Stock: CRISPR Therapeutics vs. Invitae ↗

December 05, 2023

One of these stocks may be riskier than the other...

Via The Motley Fool

The Market's Up This Year. Do You Feel Like You Are Winning? ↗

December 04, 2023

We've also got a look at two stocks worth watching and the popular toys for this holiday season.

Via The Motley Fool

Is CRISPR Therapeutics the Best Gene-Editing Stock? ↗

November 22, 2023

The biotech's first-mover advantage bodes well for its long-term prospects.

Via The Motley Fool

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

Where Will Vertex Pharmaceuticals Be in 10 Years? ↗

December 04, 2023

Vertex shares have soared 400% over the past decade.

Via The Motley Fool

If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today ↗

December 04, 2023

CRISPR Therapeutics' shares advanced in the double-digits this year.

Via The Motley Fool

Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now ↗

December 03, 2023

The one thing these two stocks have in common is tremendous growth prospects.

Via The Motley Fool

An Important History Lesson for Gene-Editing Investors ↗

December 02, 2023

Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.

Via The Motley Fool

5 Top Stocks to Buy Before 2024 ↗

December 02, 2023

These stocks have room to run -- next year and over the long term.

Via The Motley Fool

Five Best Performing Stocks Of The Top ETF Of November ↗

December 01, 2023

Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way.

Via Talk Markets

Topics ETFs

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

December 01, 2023

It's not as long a shot as some might think.

Via The Motley Fool

Looking for Growth? 2 Top Stocks to Buy Hand Over Fist ↗

December 01, 2023

These stocks offer enormous long-term growth potential.

Via The Motley Fool

3 Biotech Stocks That Could Be Multibaggers in the Making ↗

November 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Via InvestorPlace

Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception ↗

November 29, 2023

The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.

Via Benzinga

Topics ETFs

Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback' ↗

November 29, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here.

Via Benzinga

3 Top-Rated Biotech Stocks That Analysts Are Loving Now ↗

November 28, 2023

Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.

Via InvestorPlace

2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market ↗

November 28, 2023

These stocks may take off in a market favoring growth.

Via The Motley Fool

Investing in These 3 Stocks Now Could Make You a Millionaire Retiree ↗

November 25, 2023

These innovators should have tremendous long-term growth prospects.

Via The Motley Fool

3 Biotech Stocks That Could Be Millionaire Makers ↗

November 22, 2023

Many biotech stocks offer exciting long-term growth prospects.

Via The Motley Fool

Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗

November 20, 2023

ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.

Via Talk Markets

Topics ETFs

What's Going On With Crispr Therapeutics Stock Monday? ↗

November 20, 2023

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory authorization of the company's

Via Benzinga

Google’s Bard AI Says These 3 Stocks Will Rise 1,000% ↗

November 20, 2023

Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential.

Via InvestorPlace

Topics Artificial Intelligence

2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street ↗

November 20, 2023

Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?

Via The Motley Fool

Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire? ↗

November 19, 2023

The stock is trading below its peak, reached a couple of years ago.

Via The Motley Fool

3 Monster Stocks in the Making ↗

November 18, 2023

These stocks could grow much larger over the next few years.

Via The Motley Fool

Why CRISPR Therapeutics Stock Is Jumping Again Today ↗

November 17, 2023

The stock continues to enjoy momentum from a key regulatory approval.

Via The Motley Fool

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.